SCHEMBL29636675

SCHEMBL29636675

NCCCNc1cc(-c2ccco2)nc2ccccc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 2/20 0.68
SLC2A1 P11166 1/20 0.54
KDM4E B2RXH2 6/20 0.50
GLA P06280 4/20 0.50
ALDH1A1 P00352 4/20 0.50
POLB P06746 4/20 0.50
GAA P10253 3/20 0.50
HPGD P15428 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
ESR1 P03372 1/20 0.50
TP53 P04637 1/20 0.50
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CACNA1B Q00975 1/20 0.49
APBA1 Q02410 1/20 0.49
CTDSP1 Q9GZU7 2/20 0.48
APOBEC3A P31941 1/20 0.48
HTT P42858 1/20 0.48
ESR2 Q92731 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23015082 1.00 ACP1 (0.68) ACP1SLC2A1KDM4EGLAALDH1A1
SCHEMBL17688792 0.81 ACP1 (1.00) ACP1
SCHEMBL28237712 0.77 KDM4E (0.57) ACP1KDM4EGLAALDH1A1POLB
SCHEMBL6753691 0.77 SLC2A1 (0.62) ACP1SLC2A1
Hydrochloric Acid SCHEMBL899167 0.74 CYP2C19 (0.70) SLC2A1L3MBTL1
SCHEMBL29636689 0.74 ACP1 (0.73) ACP1
SCHEMBL23015135 0.74 ACP1 (0.73) ACP1
SCHEMBL23015129 0.73 SLC2A1 (0.51) ACP1SLC2A1
SCHEMBL23722921 0.73 CACNA1B (0.75) KDM4EGLAALDH1A1POLBGAA
SCHEMBL29636738 0.73 SLC2A1 (0.51) ACP1SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4017492-A1 MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS Biohaven Therapeutics Ltd. (US) 2022-06-29 EP claimed
CN-114667145-A Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders 拜尔哈文制药股份有限公司 2022-06-24 CN claimed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
CN-114667145-A Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders 拜尔哈文制药股份有限公司 2022-06-24 CN disclosed